Top 50 Global Leading Biotech Venture Capital Funds

The funds span a diverse mix of strategies, from early-stage biotech specialists like SciFounders and Pillar VC to multistage powerhouses such as NEA, Sequoia, and Khosla Ventures. Together, they reflect where biotech innovation is scaling fastest and where capital is being deployed with conviction.

Geographically, the United States remains dominant, particularly in hubs like San Francisco, Menlo Park, Boston, Seattle, and New York. Europe contributes strong players in London, Geneva, Berlin, and Tallinn, while Asia adds momentum through funds like ZhenFund in China. The map is clear: biotech capital formation is increasingly global.

Most leading biotech VCs concentrate on early-stage investing such as Pre-Seed, Seed, and Series A, backing entrepreneurs at the frontier of science. At the same time, heavyweight investors like Khosla Ventures, Menlo Ventures, and Andreessen Horowitz anchor later-stage growth with substantial multi-stage vehicles.

The most common sector themes include:

Life Sciences & Therapeutics: NEA, Canaan, Bessemer

Synthetic Biology & Deep Biotech: Pillar VC, Refactor Capital, Breakout Ventures

HealthTech & Digital Biology: DCVC, Obvious Ventures, AV8, BlueYard

Generalist Funds with Biotech Strength: Sequoia, Index Ventures, Kleiner Perkins, Andreessen Horowitz

This curated roundup provides a snapshot of the strategic direction of biotech venture capital, where thesis-driven investors are concentrating and how they are shaping the next decade of health innovation.

Whether you are a founder raising capital or an LP mapping the landscape, this list captures where the most impactful biotech capital is being deployed.

Explore the full list of Top 50 Global Leading Biotech Venture Capital Funds, including their sector focus, stage, fund size, and global HQ - now live on VCArchive.